PharmaResources (Shanghai) Co. Ltd. A (301230) — Net Asset Quality Index
PharmaResources (Shanghai) Co. Ltd. A (301230) has a Net Asset Quality Index of 78.3% as of March 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥1.32 Billion minus total liabilities of CN¥285.89 Million yields net assets of CN¥1.03 Billion. A higher index indicates a stronger, lower-leverage balance sheet. See PharmaResources (Shanghai) Co. Ltd. A liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Quality Index
Net Assets
Total Assets
Total Liabilities
PharmaResources (Shanghai) Co. Ltd. A Net Asset Quality Index Over Time (2020–2025)
This chart shows how PharmaResources (Shanghai) Co. Ltd. A's Net Asset Quality Index has evolved across 6 annual periods from 2020 to 2025. As of March 2026, the index stands at 78.3%, representing net assets of CN¥1.03 Billion against total assets of CN¥1.32 Billion CNY. Explore 301230 cash generation efficiency to assess how effectively this company generates cash.
Annual Net Asset Quality Index for PharmaResources (Shanghai) Co. Ltd. A (2020–2025)
The table below presents the year-by-year Net Asset Quality Index for PharmaResources (Shanghai) Co. Ltd. A from 2020 to 2025, covering 6 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see PharmaResources (Shanghai) Co. Ltd. A market cap and net worth.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 76.4% | CN¥1.00 Billion | CN¥1.31 Billion | CN¥309.87 Million | ▼ -2.0 pp |
| 2024 | 78.4% | CN¥1.03 Billion | CN¥1.32 Billion | CN¥283.73 Million | ▲ +3.3 pp |
| 2023 | 75.1% | CN¥1.12 Billion | CN¥1.49 Billion | CN¥369.62 Million | ▼ -10.4 pp |
| 2022 | 85.5% | CN¥1.11 Billion | CN¥1.30 Billion | CN¥188.38 Million | ▲ +23.1 pp |
| 2021 | 62.5% | CN¥348.44 Million | CN¥557.81 Million | CN¥209.37 Million | ▼ -7.9 pp |
| 2020 | 70.4% | CN¥263.18 Million | CN¥373.99 Million | CN¥110.81 Million | — |